Who to call at Daiichi Sankyo Healthcare Co, and when
Fundz watches for the moments Daiichi Sankyo Healthcare Co starts buying, and tells you who to reach.
- An alert the day Daiichi Sankyo Healthcare Co raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Daiichi Sankyo Healthcare Co, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Daiichi Sankyo Healthcare Co. With Fundz connected, it knows.
Daiichi Sankyo and iDEL Therapeutics Forge Global Research Partnership for Cancer Drug Development.
Contract Type
partnership
TokyoBiotechnologyHealth CarePharmaceuticalDescription
Daiichi Sankyo and iDEL Therapeutics have entered a multi-year global research collaboration to develop a new multi-drug conjugate platform aimed at targeted delivery into solid tumor cells. This collaboration is expected to enhance Daiichi Sankyo's oncology product offerings and address significant drug delivery challenges.
Quick answer
Daiichi Sankyo and iDEL Therapeutics Forge Global Research Partnership for Cancer Drug Development. (November 10, 2026). Daiichi Sankyo Healthcare Co is based in Tokyo, Japan.
- What agreement did Daiichi Sankyo Healthcare Co announce on November 10, 2026?
- Daiichi Sankyo and iDEL Therapeutics have entered a multi-year global research collaboration to develop a new multi-drug conjugate platform aimed at targeted delivery into solid tumor cells. This collaboration is expected to enhance Daiichi Sankyo's oncology product offerings and address significant drug delivery challenges.
- What does Daiichi Sankyo Healthcare Co do?
- Daiichi Sankyo Healthcare Co specializes in consumer healthcare products, including OTC medicines, skincare, and nutritional items.
- Where is Daiichi Sankyo Healthcare Co based?
- Daiichi Sankyo Healthcare Co is based in Tokyo, Japan.
- Which similar companies announced agreements around the same time?
- Essential Pharma (November 9, 2026), Sino Biopharmaceutical (November 13, 2026), Spektus Pharma (November 13, 2026) and Pfizer (November 14, 2026) also announced agreements within 45 days of Daiichi Sankyo Healthcare Co.
Source: Fundz verified event record.
Other recent agreements in Pharmaceutical and Biotechnology
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Essential Pharma and Nordmark establish partnership for UK availability of Norzyme® capsules for pancreatic insufficiency. (November 9, 2026)
- Sino Biopharmaceutical Partners with Boehringer Ingelheim in a $358 Million Oncology Deal (November 13, 2026)
- Spektus Pharma and GEBRO Holding Form Partnership for Global Commercialisation of ActraFlex® (November 13, 2026)
- Pfizer Partners with Blackstone Life Sciences to Co-Fund $1.5 Billion Development for Berobenatide Obesity Drug. (November 14, 2026)
- AbbVie partners with McLaren Racing in a multiyear collaboration to promote liver health awareness through Formula 1. (November 3, 2026)
- Teva and Samsung Bioepis Sign Agreement for U.S. Rights to Biosimilars Infliximab and Etanercept. (November 3, 2026)
Agreement Insights
What this usually meansDaiichi Sankyo Healthcare Co signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.